For example, genetic polymorphisms, such as the APOE ε4 allele associated with an increased burden of cerebral microbleeds, as well as those related to lipid metabolism or inflammation could modulate the impact of NHR or the Albumin to Globulin ratio on CMBs risk. The gene discussed is APOE; the disease is cerebral microbleeds.